Trevi Therapeutics, Inc. (TRVI)
| Market Cap | 2.61B +190.4% |
| Revenue (ttm) | n/a |
| Net Income | -45.61M |
| EPS | -0.32 |
| Shares Out | 141.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,515,030 |
| Open | 18.04 |
| Previous Close | 18.09 |
| Day's Range | 17.81 - 18.65 |
| 52-Week Range | 6.55 - 20.22 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 26.18 (+42.28%) |
| Earnings Date | Aug 6, 2026 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price target is $26.18, which is an increase of 42.28% from the latest price.
News
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
Serina Therapeutics (SER) announced the appointment of Farrell Simon to its board of directors, effective immediately. Simon will also serve on the board’s audit and compensation committees. He curren...
Trevi Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Trevi Therapeutics (TRVI) with an Outperform rating and $36 price target The company’s Haduvio has potential to be a first-in-class opportunity in idiopathic pulmonar...
Trevi Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Trevi Therapeutics (TRVI) with an Outperform rating and $36 price target
Trevi Therapeutics price target raised to $31 from $21 at B. Riley
B. Riley raised the firm’s price target on Trevi Therapeutics (TRVI) to $31 from $21 and keeps a Buy rating on the shares. GSK’s (GSK) decision to halt camlipixant in…
Trevi Therapeutics price target raised to $24 from $21 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Trevi Therapeutics (TRVI) to $24 from $21 and keeps a Buy rating on the shares. The firm sees no negative read-through to…
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $40 from $29 and keeps a Buy rating on the shares after GSK (GSK) discontinued camlipixant in refractory…
Trevi Therapeutics rises 10.9%
Trevi Therapeutics (TRVI) is up 10.9%, or $1.89 to $19.25.
Trevi Therapeutics rises 10.4%
Trevi Therapeutics (TRVI) is up 10.4%, or $1.80 to $19.16.
Trevi Therapeutics management to meet with Cantor Fitzgerald
Meeting to be held in London on July 14 hosted by Cantor Fitzgerald.
Trevi Therapeutics Announces Upcoming June and July Event Schedule
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics Transcript: AGM 2026
The meeting covered board introductions, five key proposals, and voting procedures. All proposals, including director election, auditor ratification, executive compensation, stock plan, and share increase, were approved. No questions were raised by shareholders.
Trevi Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
A differentiated therapy for chronic cough is advancing through pivotal trials in IPF and RCC, with strong efficacy and safety data, a large addressable market, and a robust financial position to support development through 2030. Key data readouts are expected in 2027–2028.
Trevi Therapeutics price target raised to $30 from $18 at Stifel
Stifel analyst Annabel Samimy raised the firm’s price target on Trevi Therapeutics (TRVI) to $30 from $18 and keeps a Buy rating on the shares.
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $29 from $21 and keeps a Buy rating on the shares. The company’s key opinion leader event has…
Trevi Therapeutics Transcript: Investor Day 2026
The event outlined a focused strategy to lead in chronic cough with Haduvio, advancing pivotal trials in IPF, non-IPF ILD, and RCC, supported by strong financials and patent protection. Large, underserved markets and rapid physician adoption are expected, with peak sales potential of $6B across indications.
Trevi Therapeutics Slides: FY 2026
Trevi Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 7, 2026.
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $18 and keeps an Overweight rating on the shares after the company provided its first quarter…
Trevi Therapeutics Earnings Call Transcript: Q1 2026
Clinical programs for IPF, non-IPF ILD, and RCC chronic cough are advancing, with strong cash reserves and extended runway into 2030. New patents strengthen IP, and key trial readouts are expected in late 2026 and 2027.
Trevi Therapeutics Earnings release: Q1 2026
Trevi Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Trevi Therapeutics Quarterly report: Q1 2026
Trevi Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and contin...
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse...
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...